Experimental advance of targeted medicines for chronic myeloid leukemia--review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 211-214, 2007.
Artículo
en Chino
| WPRIM
| ID: wpr-230298
ABSTRACT
Chronic myelogenous leukemia (CML) is a myeloproliferative disorder from hematopoietic stem cell disorder characterized by the consecutive expression of bcr-abl gene, and the translation product of which has enhanced tyrosine kinase activity and can activate a series of downstream signal transduction proteins and results in the occurence of CML. Although the application of imatinib (IM) makes nearly all patients with CML in chronic phase achieve a complete hematologic remission, and 90%of those treated in the early chronic phase achieve a complete cytogenetic remission, but the development of resistance to IM in the course of treatment and even in the beginning of the treatment forced people to develop new agents and to combine the new agents with IM in order to achieve better therapeutic result. This article reviews the experimental advances of targeted therapeutics in CML recent years.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Piperazinas
/
Pirimidinas
/
Benzamidas
/
Proteínas Tirosina Quinasas
/
Leucemia Mielógena Crónica BCR-ABL Positiva
/
Proteínas Proto-Oncogénicas c-abl
/
Sistemas de Liberación de Medicamentos
/
Inhibidores de Proteínas Quinasas
/
Quimioterapia
/
Proteínas Proto-Oncogénicas c-bcr
Límite:
Humanos
Idioma:
Chino
Revista:
Journal of Experimental Hematology
Año:
2007
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS